08.12.2015 - US drugmaker Eli Lilly is ending development of its injectable basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes, to focus on other, more...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)